ATLANTA, Dec. 1, 2017 /PRNewswire/ -- CryoLife, Inc. CRY, a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of JOTEC AG, a German-based, privately-held developer of technologically differentiated endovascular stent grafts, and cardiac and vascular surgical grafts, focused on aortic repair.
About CryoLife
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable living tissues used in cardiac and vascular surgical procedures. CryoLife markets and sells a highly competitive product portfolio focused on treating aortic disease in more than 80 countries worldwide. For additional information about CryoLife, visit our website, www.cryolife.com.
Contacts: |
|
CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and |
The Ruth Group Zack Kubow 646-536-7020 |
View original content with multimedia:http://www.prnewswire.com/news-releases/cryolife-completes-acquisition-of-jotec-300565402.html
SOURCE CryoLife, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.